Table 3.
Drug–drug interactions: effect on teneligliptin pharmacokinetics
| Combination | Dose (mg/day) | n | Cmax (ng/mL)a | AUC∞ (ng·h/mL)a | t½ (h)a | Ratio to teneligliptin alone (90% CI)b | ||
|---|---|---|---|---|---|---|---|---|
| C max | AUC∞ | t ½ | ||||||
| Ketoconazole [37] | ||||||||
| Teneligliptin alone | 20 | 14 | 222.8 (43.5) | 2039.6 (265.3) | 20.7 (4.2) | |||
| Teneligliptin + ketoconazole | 20 | 14 | 308.8 (77.6) | 3064.1 (523.5) | 21.8 (3.9) | 1.37 (1.25, 1.50) | 1.49 (1.39, 1.60) | 1.06 (0.95, 1.18) |
| Metformin [38] | ||||||||
| Teneligliptin alone | 40 | 19 | 446.3 (62.7) | 3352.0 (538.5)c | ||||
| Teneligliptin + metformin | 40 | 19 | 405.7 (63.9) | 3477.9 (459.7)c | 0.91 (0.85, 0.97) | 1.04 (1.00, 1.09) | ||
| Glimepiride [31] | ||||||||
| Teneligliptin alone | 40 | 16 | 545.4 (169.0) | 3970.0 (710.5) | 22.6 (5.9) | |||
| Teneligliptin + glimepiride | 40 | 16 | 523.1 (134.9) | 3663.6 (604.9) | 24.9 (5.5) | 0.97 (0.87, 1.09) | 0.93 (0.89, 0.96) | 1.10 (0.97, 1.26) |
| Pioglitazone [31] | ||||||||
| Teneligliptin alone | 40 | 16 | 503.3 (151.0) | 3820.2 (440.6) | 24.7 (5.5) | |||
| Teneligliptin + pioglitazone | 40 | 16 | 549.7 (109.0) | 3836.1 (412.1) | 22.7 (5.3) | 1.12 (0.98, 1.27) | 1.01 (0.97, 1.05) | 0.92 (0.82, 1.03) |
| Canagliflozin [39] | ||||||||
| Teneligliptin alone | 40 | 18 | 458.3 (78.8) | 3781.2 (646.3) | 24.0 (6.5) | |||
| Teneligliptin + canagliflozin | 40 | 18 | 444.9 (66.6) | 3699.5 (743.6) | 22.1 (4.8) | 0.98 (0.90, 1.06) | 0.98 (0.93, 1.02) | 0.93 (0.82, 1.06) |
AUC∞ area under the plasma concentration time-curve from time zero to infinity, AUC24 AUC from time zero to 24 h, Cmax maximal plasma concentration, t½ elimination half-life, CI confidence interval
aMean (standard deviation)
bResults are reported as ratios of geometric means and the respective 90% confidence intervals
cAUC24